Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 9/20 | 0.46 |
| ▸ | AKT2 | P31751 | 8/20 | 0.46 |
| ▸ | CKS1B | P61024 | 3/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5266638 | 0.90 | AKT1 (0.48) | AKT1AKT2ADORA3 | |
| SCHEMBL5261658 | 0.86 | ALDH1A1 (0.51) | AKT1AKT2METAP2CYP1A2CYP2E1 | |
| SCHEMBL5263100 | 0.82 | AKT1 (0.45) | AKT1AKT2NPC1RAB9AALOX5 | |
| SCHEMBL5264967 | 0.82 | AKT1 (0.45) | AKT1AKT2NPC1RAB9AALOX5 | |
| SCHEMBL5259567 | 0.81 | AKT1 (0.44) | AKT1AKT2NPC1RAB9AALOX5 | |
| SCHEMBL5261912 | 0.81 | AKT1 (0.47) | AKT1AKT2CYP1A2NPC1RAB9A | |
| SCHEMBL5264520 | 0.78 | AKT1 (0.45) | AKT1AKT2NPC1RAB9ATP53 | |
| SCHEMBL5262618 | 0.77 | AKT1 (0.48) | AKT1AKT2CYP1A2NPC1RAB9A | |
| SCHEMBL5262073 | 0.76 | AKT1 (0.48) | AKT1AKT2CKS1BSKP2NPC1 | |
| SCHEMBL5264876 | 0.76 | AKT1 (0.51) | AKT1AKT2CYP3A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660500-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES FOR THE PREVENTION AND TREATMENT OF CANCER | S A L V A T LAB SA (ES) | 2007-12-12 | — | — | EP | disclosed |
| US-20060189631-A1 | Substituted imidazopyrimidines for the prevention and treatment of cancer | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189631-A1 | Substituted imidazopyrimidines for the prevention and treatment of cancer | BRCA1, CCNA1, DPYD | AKT1 3579/4885AKT2 3297/4885CKS1B 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.